Integra LifeSciences (IART) Expected to Announce Earnings on Thursday

Integra LifeSciences (NASDAQ:IART - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $0.43 per share and revenue of $395.06 million for the quarter. Integra LifeSciences has set its Q2 2025 guidance at 0.400-0.450 EPS and its FY 2025 guidance at 2.190-2.290 EPS.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 1.78% and a positive return on equity of 12.12%. The firm had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. During the same period in the prior year, the business earned $0.55 earnings per share. The company's revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Price Performance

IART stock traded down $0.09 during trading on Thursday, hitting $12.71. 921,360 shares of the stock traded hands, compared to its average volume of 975,948. The company has a current ratio of 1.21, a quick ratio of 0.72 and a debt-to-equity ratio of 0.81. The stock has a market cap of $987.69 million, a price-to-earnings ratio of -33.45, a P/E/G ratio of 0.71 and a beta of 1.15. Integra LifeSciences has a one year low of $11.06 and a one year high of $32.49. The company has a 50 day simple moving average of $12.62 and a 200 day simple moving average of $18.05.

Analyst Ratings Changes

IART has been the subject of several research reports. JMP Securities lowered their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. JPMorgan Chase & Co. lowered their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company lowered their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Truist Financial lowered their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $18.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock valued at $36,515,000 after buying an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company's stock worth $5,373,000 after purchasing an additional 45,693 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company's stock worth $889,000 after purchasing an additional 1,975 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences in the first quarter worth $277,000. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.